Maternal Stress on Human Milk and Infant Outcomes
- Conditions
- Preterm LaborPostpartum Depression
- Interventions
- Behavioral: Mindfulness-based intervention (with a focus on self-compassion; MBSC)
- Registration Number
- NCT04821544
- Lead Sponsor
- University of Idaho
- Brief Summary
The overarching purpose of this study is to determine if a modified 8-week mindfulness-based intervention (with a focus on self-compassion; MBSC) or 8 weeks of 2000 IU vitamin D supplementation will reduce stress and increase self-compassion in mothers of preterm infants and beneficially modify the human milk produced, and subsequently improve infant health.
- Detailed Description
During every two-week period, newly admitted infants (both preterm \<37 weeks gestational age and term ≥37 weeks gestational age) at performance site Kootenai Health NICU and term infants from the Palouse region will be block randomized to control (standard of care), mindfulness intervention (modified 8-week mindfulness
-based intervention (with a focus on self-compassion; MBSC), or vitamin D supplementation (8-week 2,000 IU vitamin D3 supplementation) groups. The purpose of the nested cohorts is to minimize the postpartum time difference among cohort mothers. Each nested MBSC cohort will undergo the 8-week MBSC intervention with a focus on increasing self-compassion. The MBSC program includes previously developed daily mindfulness practices, guided meditations, routine mindfulness prompts, and four video conference group sessions with a certified mindfulness facilitator.
Maternal data: The Perceived Stress Scale (PSS) and Self-Compassion Scale-Short Form (SCS-SF) will be given to mothers from both groups pre- and post-intervention, and during the 4th week. Saliva, urine, stool, and human milk samples will be collected at the same time points as above. Additional maternal data include: age, race, height, weight (pre-pregnancy and last weight before delivery), parity, delivery mode, chorioamnionitis, preeclampsia, HELLP (hemolysis, elevated liver enzymes, and low platelet) syndrome, antenatal antibiotics, anti-depressants or other mood-altering/neurochemical medications (current and during pregnancy), diagnosis of depression or other mental illness within the previous 5 years, history of postpartum depression and postpartum psychosis, diabetes, hypertension, heart disease, and any inflammatory or autoimmune diseases.
Infant data: Gestational age, birth weight, ventilation requirement, surgical interventions, patent ductus arteriosus, growth, nutrition prescriptions, saliva, urine and stool samples.
Data collection: All data (not including biosamples) will be collected using REDCap hosted within the UI system.
Sample measurements: Maternal salivary cortisol (marker of stress) and oxytocin (marker of anxiety and "social-closeness") concentrations will be measured using ELISA. Human milk proteins will be identified using mass spectrometry-based proteomics. Following proteomic analyses, targeted proteins will be quantified using ELISA and Western Blot. Both maternal and infant saliva, urine and stool samples will be used for metabolomic and transcriptomic sequencing to identify metabolic and molecular changes, respectively, in both mothers and infants. Infant systemic oxidative stress will be measured through urine F2-isoprostanes concentrations (ELISA), and infant intestinal inflammation will be determined with stool calprotectin concentrations (ELISA).
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 500
- Mothers of newborn infants at Kootenai Health NICU and the Palouse region
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Mindfulness-based intervention (with a focus on self-compassion; MBSC) Mindfulness-based intervention (with a focus on self-compassion; MBSC) 8-week MBSC intervention with a focus on increasing self-compassion. The MBSC program includes previously developed daily mindfulness practices, guided meditations, routine mindfulness prompts, and four video conference group sessions with a certified mindfulness facilitator.
- Primary Outcome Measures
Name Time Method Maternal Stress - Biomarker Change Baseline to 4 and 8 weeks Salivary cortisol - Change from Baseline cortisol to 4 and 8 weeks
Maternal Stress - Psychometric Measure Change Baseline to 4 and 8 weeks Perceived Stress Scale (PSS) - Change from Baseline PSS to 4 and 8 weeks
The Perceived Stress Scale (PSS) is validated and the most widely used instrument to measure perception of stress. The PSS includes 14 questions inquiring about feelings and thoughts during the past month expressed through frequency. The PSS will be used pre-intervention, post-intervention (8 weeks), and at the mid-point of the intervention (4 weeks). The scale for each question ranges from 0-4. The PSS measures how often the responder found life to be unpredictable, uncontrollable, and overloaded. Higher score indicates higher perceived stress. The total score ranges between 0-56.Maternal Self-compassion - Biomarker Change Baseline to 4 and 8 weeks Salivary oxytocin - Change from Baseline oxytocin to 4 and 8 weeks
Maternal Self-compassion - Psychometric Measure Change Baseline to 4 and 8 weeks Self-Compassion Scale-Short Form (SCS-SF) - Change from Baseline SCS-SF to 4 and 8 weeks
The Self-Compassion Scale-Short Form (SCS-SF)19 is a shortened and highly correlated (r ≥ 0.97) scale (12 items) from the original 26-item SCS. The SCS-SF measures six key components of self-compassion using a scale that ranges from 1-5: self-kindness, self-judgement, common humanity, isolation, mindfulness, and over-identification. Self-compassion is associated with psychological well-being and is therefore often measured alongside stress and anxiety. High score indicates higher self-compassion. The total score ranges between 0-60.
- Secondary Outcome Measures
Name Time Method Human Milk Proteins & Peptides Change Baseline to 4 and 8 weeks Protein and peptide profiles will be measured using proteomic \& peptidomic analyses to assess human milk protein and peptide changes from baseline to 4 and 8 weeks as a function of maternal changes in stress/self-compassion. These are measured outcomes.
Maternal Metabolomic & Transcriptomic Changes Baseline to 4 and 8 weeks Maternal metabolomic pathways \& gene activation changes from baseline to 4 and 8 weeks in response to changes in stress/self-compassion. These are measured outcomes.
Infant Metabolomic & Transcriptomic Changes Baseline to 4 and 8 weeks Infant metabolomic pathways \& gene activation changes from baseline to 4 and 8 weeks in response to maternal changes in stress/self-compassion, and human milk protein/peptide profile changes. These are measured outcomes.
Maternal Vitamin D Changes Baseline to 4 and 8 weeks Maternal vitamin D status changes in both serum and human milk from baseline to 4 and 8 weeks.
Trial Locations
- Locations (1)
Kootenai Health
🇺🇸Coeur d'Alene, Idaho, United States